Floxuridine
- Generic Name
- Floxuridine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11FN2O5
- CAS Number
- 50-91-9
- Unique Ingredient Identifier
- 039LU44I5M
- Background
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gas...
- Indication
For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion).
- Associated Conditions
- Stage 4 gastrointestinal adenocarcinoma
- Associated Therapies
- Palliative Treatment
HAI-Floxuridine, or SIRT, Combined with Gemox for Patients with Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06313203
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 408
- Registration Number
- NCT05863195
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT05286814
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT04898504
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT04552093
- Locations
- 🇳🇱
Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Netherlands
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT04251715
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Hepatic Artery Infusion Pump for NPC Liver Metastases
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 16
- Registration Number
- NCT03876574
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
- Conditions
- Interventions
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 92
- Registration Number
- NCT03678428
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT03493061
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01938729
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.